Search hospitals > California > Santa Monica
Clinical Science Institute
Claim this profileSanta Monica, California 90404
Global Leader in Atopic Dermatitis
Global Leader in Psoriasis
Conducts research for Plaque Psoriasis
Conducts research for Medical Device Dermatitis
Conducts research for Eczema
88 reported clinical trials
2 medical researchers
Summary
Clinical Science Institute is a medical facility located in Santa Monica, California. This center is recognized for care of Atopic Dermatitis, Psoriasis, Plaque Psoriasis, Medical Device Dermatitis, Eczema and other specialties. Clinical Science Institute is involved with conducting 88 clinical trials across 39 conditions. There are 2 research doctors associated with this hospital, such as Paul Yamauchi and Paul Steven Yamauchi.Top PIs
Paul YamauchiClinical Science Institute4 years of reported clinical research
Studies Plaque Psoriasis
Studies Atopic Dermatitis
13 reported clinical trials
13 drugs studied
Paul Steven YamauchiClinical Science Institute7 years of reported clinical research
Studies Atopic Dermatitis
Studies Medical Device Dermatitis
4 reported clinical trials
3 drugs studied
Clinical Trials running at Clinical Science Institute
Atopic Dermatitis
Eczema
Chronic Urticaria
Systemic Lupus Erythematosus
Cutaneous Lupus Erythematosus
Medical Device Dermatitis
Plaque Psoriasis
Discoid Lupus
Amlitelimab
for Eczema
This trial is testing amlitelimab, a medication for adults with moderate to severe atopic dermatitis who were in a previous trial. The study aims to see if the medication is safe and effective over an extended time. Amlitelimab works by calming the immune system to reduce skin inflammation.
Recruiting1 award Phase 2 & 3
Amlitelimab
for Eczema
This is a multinational, multicenter, randomized, double-blind, placebo-controlled, parallel, Phase 3 study for treatment of participants aged 12 years and older diagnosed with moderate-to-severe atopic dermatitis (AD). The main objective of this study is to evaluate if those participants who received amlitelimab dose 1 in the parent studies (EFC17559 \[COAST-1\], EFC17560 \[COAST 2\], EFC17561 \[SHORE\]) and were responders can maintain their response either remaining at dose 1 or switching to dose 2 of amlitelimab compared to treatment withdrawal. Study details include: The study duration will be up to 68 weeks including a 52-week randomized double-blind period, and a 16-week safety follow-up for participants not entering the LTS17367 (RIVER-AD). The study duration will be up to 52 weeks for participants entering the LTS17367 \[RIVER-AD\] study at the Week 52 visit of EFC17600 (ESTUARY). The total treatment duration will be up to 52 weeks. The total number of visits will be up to 15 visits (or 14 visits for those entering LTS17367 \[RIVER-AD\] study).
Recruiting1 award Phase 33 criteria
Barzolvolimab
for Eczema
The purpose of this study is to assess the efficacy and safety of barzolvolimab in adults with Atopic Dermatitis
Recruiting0 awards Phase 23 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Clinical Science Institute?
Clinical Science Institute is a medical facility located in Santa Monica, California. This center is recognized for care of Atopic Dermatitis, Psoriasis, Plaque Psoriasis, Medical Device Dermatitis, Eczema and other specialties. Clinical Science Institute is involved with conducting 88 clinical trials across 39 conditions. There are 2 research doctors associated with this hospital, such as Paul Yamauchi and Paul Steven Yamauchi.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.